SpringWorks Gets FDA Approval for Desmoid Tumor Treatment
28 11월 2023 - 8:46AM
Dow Jones News
By Ben Glickman
SpringWorks Therapeutics has received approval from the Food and
Drug Administration for its treatment of desmoid tumors.
The Stamford, Conn.-based biopharmaceutical company said that
Ogsiveo had been approved for adults with progressing desmoid
tumors who require systemic treatment.
Desmoid tumors are non-cancerous, soft-tissue tumors which can
be life-threatening when they impact vital structures. SpringWorks
said Ogsiveo was the first FDA-approved therapy for patients with
desmoid tumors.
SpringWorks said the treatment would be available to order
through certain specialty pharmacies and distributors in five to 10
business days.
The company plans to file a marketing authorization application
for the treatment with European regulators in the first half of
2024.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
November 27, 2023 18:31 ET (23:31 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
SpringWorks Therapeutics (NASDAQ:SWTX)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
SpringWorks Therapeutics (NASDAQ:SWTX)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
